Company Reports

Icon is one of a handful of global contract research organizations with the infrastructure to carry out large, late-stage clinical trials. While Icon operates on a significant global scale with extensive regulatory knowledge, we no longer view its advantages as durable enough to maintain adjusted returns on invested capital exceeding its cost of capital over the next decade.

Icon reported revenue of $2.06 billion in the second quarter, up 1.2% from the prior-year period. Net business wins in the quarter were $3.1 billion, and the backlog increased 3% sequentially to $23.4 billion. Management maintained its 2026 guidance, including revenue of $8 billion at the midpoint.

Icon's stock jumped nearly 11% on June 24 after it reported first-quarter results highlighted by net business wins of nearly $2.9 billion and a net book/bill ratio of 1.42 times. First-quarter revenue of $2.03 billion represented an increase of 0.9% compared with the prior-year period.

Icon's stock soared over 15% on May 28 as its accounting investigation revealed revenue overstatements of 0.8% of 2023 revenue and 1.1% of 2024 revenue. Icon reported its delayed 2025 results, with revenue of $8.25 billion, up 0.8% year over year.

While Icon operates on a global scale with expertise in clinical trials and regulatory processes, we no longer view its advantages as durable enough to maintain adjusted returns on invested capital exceeding its cost of capital over the next decade.

Icon is one of a handful of global contract research organizations with the infrastructure to carry out large, late-stage clinical trials. While Icon operates on a significant global scale with extensive regulatory knowledge, we no longer view its advantages as durable enough to maintain adjusted returns on invested capital exceeding its cost of capital over the next decade.

Icon delayed its fourth-quarter and 2025 financial results amid its ongoing accounting review, with preliminary findings suggesting the company's revenue for fiscal years 2023 and 2024 may have been overstated by less than 2%. It also withdrew its previously issued 2025 guidance.

Icon has the capabilities and expertise to execute late-stage contract research effectively, including global reach, full-service offerings, extensive regulatory and clinical knowledge, and investment in innovation and technology. Icon is one of a handful of contract research organizations with the global infrastructure to carry out these late-stage, multinational clinical trials.

Icon's stock plummeted about 40% on Feb. 12, as the firm announced an accounting investigation initiated by the Audit Committee of Icon's board of directors. Preliminary results indicate the company's operating revenue for fiscal years 2023 and 2024 may have been overstated by less than 2%.

Icon reported over $2 billion in revenue in the third quarter, up 1.3% from the prior-year period. Adjusted EBITDA was nearly $397 million in the quarter, or 19.4% of revenue. Management raised its 2025 revenue guidance by about 1% at the midpoint.

Icon delivered gross business wins of $2.97 billion in the second quarter, representing a 10% increase compared with the first quarter of 2025. Investors reacted positively and sent the stock up 14%.

Narrow-moat Icon is navigating a challenging macroeconomic environment, which has led to elevated cancellation levels due to a range of reasons, including portfolio reprioritizations and futility decisions. Management lowered its 2025 revenue guidance by 5% at the midpoint, which reflects elevated cancellations and the exclusion of two large next-generation covid vaccine trials that had a sponsor-induced delay, and we adjusted our near-term forecast accordingly. We now forecast 2025 revenue of roughly $7.95 billion, a 4% decline year over year. Reflecting this slower near-term growth, we lowered our fair value estimate to $243 per share from $268. However, the stock is trading in 5-star territory, presenting an attractive opportunity for a long-term investor.

We believe Icon possesses all the necessary elements to maintain a strong position in the late-stage contract research organization market: global capabilities, full-service offerings, extensive regulatory and clinical expertise, investment in innovation and technology, and operational excellence. Icon is one of a handful of CROs with the global infrastructure to carry out late-stage, multinational trials and hone international regulatory expertise.

Narrow-moat Icon is continuing to work through a challenging macroeconomic environment, as some of its customers are undergoing budget cuts and reprioritizations of their pipeline candidates. However, there are positive signs that demonstrate Icon’s resilience and support its narrow moat rating. Icon’s backlog at quarter-end was $24.7 billion, an increase of 8.3% from the fourth quarter of 2023. Full-year net business wins were $9.97 billion, and it reported a healthy net book-to-bill ratio of 1.20 times on a trailing 12-month basis. Icon’s results were better than anticipated, and investors reacted positively by sending the stock up over 5%. Icon is tracking our expectations, and we maintain our fair value estimate of $268 per share. The stock is trading in 4-star territory, presenting an attractive opportunity for a long-term investor.

We believe Icon possesses all the necessary elements to maintain a strong position in the late-stage contract research organization market: global capabilities, full-service offerings, extensive regulatory and clinical expertise, investment in innovation and technology, and operational excellence. Icon is one of a handful of CROs with the global infrastructure to carry out late-stage, multinational trials and hone international regulatory expertise.

Icon experienced elevated cancellations and a slower-than-expected ramp of new project work in the third quarter, which resulted in revenue declining 1.2% from the prior-year period. Due to these headwinds, management reduced its 2024 revenue guidance by 2.6% at the midpoint and slashed its adjusted earnings per share guidance by about 7.3% at the midpoint. Some of Icon’s customers are undergoing budget cuts and reprioritizations of their pipeline candidates. Investors reacted negatively, sending the stock down 20% in Oct. 24 trading, the lowest price in a year. Despite these near-term headwinds, we maintain our fair value estimate of $268 per share. We think the stock’s pullback presents an attractive opportunity for a long-term investor.

Icon reported second-quarter results highlighted by revenue of $2.1 billion, representing a nearly 5% increase from the prior-year period. However, management reduced its 2024 revenue guidance by 1.2% at the midpoint because of the impact of the strengthening US dollar and delayed trial starts related to next-generation covid vaccine work. These delays were due to a lag in sponsors receiving regulatory guidance that was required before commencing trial enrollment for new variants. Additionally, there were investigational product-related issues that caused a delay in enrollment. Management reassured investors that these studies have not been canceled, and it expects the trials will enroll the majority of patients in 2025. Delayed trial starts can happen for a variety of reasons, and we are not too concerned about it. Icon's performance has been solid, and excluding covid, revenue has grown 8% for the year to date over the first half of 2023.

Narrow-moat Icon reported strong first-quarter results highlighted by revenue exceeding $2 billion, representing a nearly 6% increase from the prior-year period, thanks to stabilizing demand within the biotech customer base. We continue to have a positive outlook for Icon, and we maintain our fair value estimate of $268 per share. However, we view the stock as currently trading at a 12% premium to our fair value estimate.

Icon ended 2023 in a healthy position with revenue of $8.12 billion, a nearly 5% increase from the previous year, and adjusted EBITDA growth exceeding 14%. We continue to have a positive outlook for the firm and have raised our fair value estimate to $268 per share from $243 based on Icon’s strong results despite challenging macroeconomic conditions. We reaffirm our narrow economic moat rating as well as our Medium Morningstar Uncertainty Rating. Despite our positive outlook, we view the stock as currently overvalued. Investors have pushed the stock up 40% since Icon reported third-quarter results in October, due to stronger-than-expected performance amid macroeconomic pressures.

We believe Icon possesses all the necessary elements to win share in the late-stage contract research organization market: global capabilities, full-service offerings, extensive regulatory and clinical expertise, investment in innovation and technology, and operational excellence. Icon is one of a handful of CROs with the global infrastructure to carry out late-stage, multinational trials and hone international regulatory expertise.